Background and objective: Inspiratory muscle training (IMT) enhances velocity of inspiratory muscle contraction and modifies inspiratory and expiratory time. This study aimed to examine the impact of high-intensity IMT (H-IMT) on exercise capacity in bronchiectasis. Methods: Forty-five patients were included. Lung function, respiratory muscle strength and endurance, exercise capacity, dyspnoea, fatigue and quality of life (QOL) were evaluated. Patients were randomized into two groups: H-IMT and control groups. Twenty-three patients underwent H-IMT for 8 weeks, using threshold loading with a target workload of maximal inspiratory pressure (MIP) of at least 70%, with 3-min cycles (as 2-min training: 1-min rest intervals) for 21 min. There was a total period of 14 min of loaded breathing and 7 min of recovery. The control group (n = 22) underwent low-intensity IMT at 10% of the initial MIP and was maintained at the same intensity until the end of the training. Results: After training, both MIP and maximal expiratory pressure (MEP) and the incremental shuttle walk distance were increased in the H-IMT group compared with the control group (P < 0.05). There was a significant difference in constant threshold load, time and pressure-time units in the H-IMT group (P < 0.05) but not in the control group (P > 0.05). A significant decrease was found in fatigue in both groups (P < 0.05). The Leicester Cough Questionnaire social score for the H-IMT group decreased significantly after the treatment (P < 0.05). Conclusion: The H-IMT increased exercise capacity in patients with non-cystic fibrosis bronchiectasis. It has also positive effects on respiratory muscle strength and endurance, and social aspects of QOL.
INTRODUCTION
Bronchiectasis is a chronic lung disease with major symptoms of cough, excessive secretions, dyspnoea, exercise intolerance and fatigue. 1, 2 Inspiratory muscle weakness may lead to muscle load and capacity discordance, and thereby, dyspnoea, decreased exercise tolerance, hypoventilation and respiratory failure. A decrease in expiratory muscle strength impairs the effectiveness of coughing and decreases the removal of airway secretions. 3, 4 Previous studies indicated respiratory muscle weakness in patients with bronchiectasis. 1, 4, 5 The underlying cause is not known, but the possible mechanisms are primary weakness and hyperinflation-related functional weakness. 6 Inspiratory muscle training (IMT) using a threshold device can enhance velocity of inspiratory muscle contraction, decreased inspiratory time and increase exhalation time and allow more time for lung emptying. 5 In bronchiectasis, one study combining IMT with whole-body exercise training (ExT) revealed that IMT has no additional effects on maximum inspiratory pressure (MIP), whereas the impact of ExT was sustained. 1 The IMT also improved both inspiratory and expiratory muscle strengths without any impact on pulmonary function, quality of life (QOL) or exercise capacity. 5 Interval-based high-intensity IMT (H-IMT) studies have been shown to provide more respiratory muscle function improvement than low-to-medium-intensity loads. 7, 8 Care to avoid fatigue by not applying H-IMT more than 3 days a week is a time-saving application compared to other methods.
As studies investigating the effects of IMT in bronchiectasis are limited, we aimed to examine the impact of isolated respiratory muscle training on significant physiological and clinical findings in bronchiectasis. Therefore, the purpose of this study was to explore the effects of H-IMT and low-IMT on exercise capacity in patients with clinically stable non-cystic fibrosis (CF) bronchiectasis. The hypothesis was that the H-IMT would cause increased exercise capacity in stable bronchiectasis.
METHODS

Subjects
Clinically stable patients with non-CF bronchiectasis aged 18-65 years were included from June 2013 to June 2016. Bronchiectasis was confirmed by clinical history, including coughing, shortness of breath, exertional dyspnoea, pulmonary function tests (PFT) and highresolution computed tomography (HRCT). Subjects, clinically stable without any evidence of an exacerbation or changes in medical therapy in the previous 3 weeks, were randomly divided into two groups based on a computer programme: H-IMT and low-intensity IMT (control). Assessors for testing were blinded to the groups. Inclusion criteria were no significant coexisting disease affecting ability to undertake exercise, ability to walk and willingness to cooperate in the study. Patients with neurological complications, advanced orthopaedic disease, advanced heart failure, acute exacerbations in the last 3 weeks, and patients on antibiotics and previously participated in a rehabilitation programme were excluded. Hacettepe University Ethics Committee approved the study (12. 06.2013, GO 13/292), which is registered at ClinicalTrials.gov (NCT02656992). All subjects gave their written informed consent to participate in the study. The primary outcome measure was incremental shuttle walk test (ISWT) distance. The power analysis was performed (G*Power Ver. 3.0.10; Franz Faul, Universität Kiel, Germany) based on two-way repeated-measures of analysis of variance. With a >27.8-m difference in the ISWT distance which is the difference between sham and intervention in the study by Newall et al., 1 80% power, 5% type I error and an effect size of 55%, 22 patients in each group were needed for sufficient sample size. The trial was ended after reaching sufficient sample size.
Measurements
Demographic and physical characteristics, smoking history and symptoms were recorded. The HRCT findings were documented. Bronchiectasis Severity Index (BSI) score was calculated. 9 All measurements were performed at the beginning and end of the 8-week programme by a blinded assessor to group allocation.
The PFT was performed using a standard spirometer (Spirodoc; MIR, Rome, Italy) and expressed as a percentage of the predicted values. 10 Dyspnoea and fatigue were evaluated using the modified Medical Research Council (MMRC) dyspnoea scale 11 and Fatigue Severity Scale (FSS), 12 respectively. Respiratory muscle strength (MIP and maximal expiratory pressure, MEP) was measured using an electronic mouth pressure device (Micro MPM; Micro Medical Ltd., Rochester, UK). The MIP and MEP were recorded as cm H 2 O and expressed as the percent predicted values. 13 Respiratory muscle endurance was measured with a threshold loading device (Powerbreathe, POWERbreathe International Ltd., Warwickshire, England), using the sustainable inspiratory pressure (SIP) test. The load was adjusted to 60% of MIP, and the duration of the trial was recorded.
14 Subjects performed respiratory efforts while breathing through the threshold loading device's rubber tubing for 10 min with a lip seal as the nose was occluded. With the use of a sustained breathing frequency of 12-14 bpm with 15-min rest intervals between two SIP tests, and taking the better of the two tests, the effects of learning and breathing technique were minimized. Heart rate (HR), oxygen saturation (SpO 2 ), respiratory rate (RR) and dyspnoea using the modified Borg Scale (mBS) were recorded before and after the test. The mBS is a 10-point categorical scale of dyspnoea on exertion. 15 Exercise capacity was evaluated using the ISWT. The test was ended if the patient reached maximal HR, SpO 2 < 80% and excessive dyspnoea, fatigue or pain. HR was evaluated using a polar HR monitor (Polar S610i; Polar Electro Oy, Kempele, Finland). SpO 2 , RR and dyspnoea (mBS) were assessed before and after the test. 16 The distance was expressed both as metres and a percentage of the predicted distance. 17 Minimal clinically significant difference for the ISWT is 35 m. 18 The QOL was measured using the Leicester Cough Questionnaire (LCQ). The scores range from 3 to 21, and higher scores indicate more impaired QOL from a cough; the questionnaire consists of physical, psychological and social dimensions. 19 
Inspiratory muscle training
The patients underwent H-IMT for 3 days/week for 8 weeks. One session/week was performed under the supervision, and the other two sessions/week were performed at home. A threshold loading device (Powerbreathe, POWERbreathe International Ltd., Warwickshire, England) was used to ensure inspiratory muscle loading. The device was previously used in bronchiectasis patients. 1 For the first session, the target workload was selected at 30% of MIP. The H-IMT group underwent IMT with a 1-min warm-up on an inspiratory load of 15% of MIP. Then, the study and rest ratio of 2:1 progressed to 30% MIP within interval IMT. No training was given during the 1-min rest period. Three-minute cycles were repeated seven times, and each session lasted 21 min. 7, 20 Following the third session, inspiratory muscle load was targeted to be at least 70% of the MIP. There was a total period of 14 min of loaded breathing and 7 min of recovery. The load was further increased over the 8-week period with the aim of titrating to a level where subjects were just able to complete the final 2-min interval. 8 In addition, a rating of perceived exertion according to the mBS score of 3-5 was taken in determining target workload at the end of each 2-min working period. The control group underwent low-intensity IMT at 10% of the initial MIP and kept the same load until the end of the training. In each group, patients were adapted to their selected patterns of breathing. 7, 20 No instructions were given to the subject regarding what breathing pattern to adopt. In each session, HR and SpO 2 were measured using a pulse oximeter (Nonin Palmsat 2550A, Noninedical Inc., Plymouth, MN, USA), and dyspnoea and rate of perceived exertion were evaluated using the mBS. Training workload was presented as the percentage of initial MIP value and pressure-time unit ( Ð Pdt). 7, 20 Tolerability was assessed using the maximum workload achieved during the H-IMT, 8 and HR, SpO 2, sensation of dyspnoea and perception of respiratory effort during progressive inspiratory loading. 21 
Statistical analysis
Statistical analysis was performed using SPSS Statistics (Version 23.0, IBM Inc., Armonk, NY, USA). An intention-to-treat analysis was performed. The Expectation Maximization (EM) method was used to overcome missing cases (two from H-IMT and one from control). The EM method is an iterative method using maximum likelihood of estimates. 22 Descriptive statistics were calculated. Normality of the data was checked using the Kolmogorov-Smirnov test. Two independent groups of numerical variables were analysed using Student's ttest or the Mann-Whitney U-test, as appropriate. The chi-square test was used for categorical comparisons. Baseline values were compared using Student's t-test. Two-way analysis of variance was used to evaluate time and group-time interaction. Repeated measures of variance was used to analyse the data in each session. The descriptive level of significance was set at P < 0.05.
RESULTS
Forty-five subjects with clinically stable bronchiectasis participated. One patient from the H-IMT group discontinued IMT due to an acute exacerbation and one patient due to inability to cooperate with the device. One patient from the control group stopped lowintensity IMT without giving any specific reason (Fig. 1 ).
Subjects were similar regarding age, gender, physical characteristics, smoking history, disease duration, aetiology of bronchiectasis, the number of acute exacerbations in the previous year, FSS and BSI scores (P > 0.05; Table 1 ). The BSI scores indicated low to intermediate in terms of severity. The PFT values respiratory muscle strength and endurance were not different between the groups (P > 0.05; Table 1 ). The number of hospitalizations was higher in the H-IMT group (P = 0.047). The MMRC scores of the H-IMT group were significantly lower than those of the control group (P < 0.05). Initial exercise HR, dyspnoea, fatigue and ISWT distance and LCQ scores except social scores (P < 0.05) were similar between the groups (P > 0.05; O.s) in the H-IMT group, and the change from the initial workload at 8 weeks was statistically significant (P < 0.05). Achieving 98% of MIP during training and no significant change in HR and SpO 2 during progressive loading (P > 0.05) indicated that H-IMT was well tolerated. The change in ISWT distance and the percent distance in the H-IMT group were significant compared to controls (P < 0.05; Table 2 ). There was no change in PFT and MMRC in either the H-IMT or the control groups (P > 0.05; Table 2 ). A significant decrease in FSS was found in both groups (P < 0.05) with no difference between the groups (P > 0.05; Table 2 ). The changes in MIP, MIP%, MEP and MEP% were significantly higher in the H-IMT group (P < 0.001; Table 2 ). There was a significant difference in SIP, time and Ð Pdt values in the H-IMT group (P < 0.05; Table 2 ). The LCQ social scores for the H-IMT group increased significantly after the treatment (P < 0.05; Table 2 ).
DISCUSSION
On the basis of the findings, an 8-week H-IMT increased exercise capacity in non-CF patients with bronchiectasis with low to intermediate severity. The H-IMT has improved respiratory muscle strength and endurance, and social aspects of the QOL. The study protocol was well tolerated.
Exercise capacity diminishes in bronchiectasis due to ventilatory changes, gas exchange problems, respiratory mechanics, cardiovascular disorders, musculoskeletal changes and psychological factors. 2, 23 We evaluated exercise capacity using the ISWT. At baseline, 69.57% of patients from the H-IMT group and 63.64% of patients from the control group were at lower than the percent predicted values of ISWT, stating a reduced exercise capacity. In two studies investigating the effects of IMT on exercise capacity in bronchiectasis, IMT was applied as 30-60% of MIP, 30 min per day, 5-7 days per week for 8 weeks. In one study, 1 the lack of an exclusive IMT group and application as a combination of ExT and IMT make comparison difficult. In the second study, 6-min walk test (6MWT) distance improved 61 m (14.89%) in the IMT group versus 20 m (4.69%) in the control group. Although not statistically significant, the baseline ISWT for the H-IMT group was 53 m further than the control group which is a randomization effect. 24 After treatment, we found a 50.3-m (7.19%) increase in the IMT group, which is above the minimal clinically significant difference. 18 However, there was a small change in the control group (0.2 m and 1.01%). The difference might be due to different characteristics of 6MWT versus ISWT. 16, 17 Other reasons may include differences in patients' age range, pulmonary function, respiratory muscle strength and IMT protocols between the studies.
Although not statistically significant, forced expiratory volume in 1 s (FEV 1 ) % predicted was 12% worse in the intervention arm. We also found no change in PFT and dyspnoea after H-IMT in patients with bronchiectasis, similar to the previous studies using IMT. 5, 8 The smoking history was minimal which is similar to the previous findings in patients with bronchiectasis. 25 The findings may reveal that H-IMT does not affect expiratory airflow and breathlessness in mild lung function impairment. Chronic fatigue is frequent in bronchiectasis and may affect exercise capacity and QOL. 26 Finding no change in fatigue may be due to having a different sample size or using the FSS, which is not a questionnaire specific to lung disease.
Two studies investigated IMT in bronchiectasis. 1, 5 In the first study, an 8-week moderate-intensity (MIP 30-60%, 15 min) IMT added to ExT did not show an increase in MIP. 1 In the second study, which had low statistical power, a programme of low-intensity IMT (MIP 30%), MIP and MEP improved by 39% and 44%, respectively, after 8 weeks. In our study, H-IMT increased MIP and MEP by 43.53% and 11.67%, respectively. The H-IMT protocol used in our study ensures achieving higher workloads without increasing dyspnoea perception. 8 Inspiration against resistance during IMT may increase the activation of the expiratory muscles by the last force extension, which may result in a significant increase in MEP. Further study is needed to clarify the mechanism of H-IMT increasing respiratory muscle function.
Respiratory muscle endurance reflects the sustained performance of a given workload. 3 No study has investigated respiratory muscle endurance during IMT. In our study, respiratory muscle endurance improved by 207 s (139%) in H-IMT and by 38 s (22%) in the control group, which were lower than the value of 261 s improvement in a meta-analysis. 27 The differences in clinical characteristics of diseases and the study protocol may be responsible for this discrepancy. The H-IMT was a high-intensity interval exercise with frequent short rest periods and resulted in the improved endurance of respiratory muscles without causing Excluded n = 22
Did not meet inclusion criteria n = 9 Refused to participate n = 13 Figure 1 Study flow chart (intention-to-treat analysis). H-IMT, high-intensity inspiratory muscle training. dyspnoea and fatigue. Whether H-IMT ensures cellular biochemical changes (increased type I fibres in the external intercostal muscles) in bronchiectasis, as in chronic obstructive pulmonary disease, 28 is unclear.
The QOL assessment is essential to understand the effects of disease on patient's life and response to intervention. Health-related QOL is affected in bronchiectasis 29 due to the symptoms, the limitations in lung function and exercise tolerance. We evaluated QOL 25-75% , forced expiratory volume 25-75%; FEV 1, forced expiratory volume in 1 s; FSS, Fatigue Severity Scale; FVC, forced vital capacity; H-IMT, high-intensity inspiratory muscle training; HRmax, maximal heart rate; ISWT, incremental shuttle walk test; LCQ, Leicester Cough Questionnaire; MEP, maximal expiratory pressure; MIP, maximal inspiratory pressure; MMRC, modified Medical Research Council; PEF, peak expiratory flow rate. using the LCQ as the validation of other questionnaires such as St George Respiratory Questionnaire (SGRQ) has not been available in Turkish before the beginning of the study. We found social dimension scores were reduced in the H-IMT group at the beginning of the study, probably due to the effects of increased number of hospitalizations and the presence of haemoptysis, reflecting the severity of the disease. Two previous studies have investigated improved QOL, measured using the SGRQ, after IMT in bronchiectasis. 1, 5 One of those studies showed that the increase in QOL when compared with the other groups was similar to that of IMT given with ExT. It was revealed that the results were preserved in this group at the end of 3 months. In the other study, IMT was shown to increase the symptoms, activity and total scores compared with the control group. 5 In our study, there was a similar increase in physical and psychological dimensions between the two groups and a significant increase in the social dimension. The aforementioned findings may be due to QOL as a subjective measurement or that the interval-based H-IMT does not make a difference regarding cough-specific QOL measured by the LCQ. In addition, the use of the LCQ which predominantly focuses on cough may limit the findings as compared with SGRQ which include other symptoms and their effects on activity.
In the present study, the H-IMT protocol was used to increase exercise capacity, respiratory muscle endurance and inspiratory muscle strength as well as dyspnoea in patients with bronchiectasis. Both the data in literature and those in our study suggest that H-IMT may be used in bronchiectasis patients as efficient to increase exercise capacity. The findings of our study revealed that respiratory muscles are capable of H-IMT, and it could be used as home-based. Thus, it may increase the patient's compliance and facilitate implementation for healthcare professionals. The limitations of the study were the number of patients included as we did not account for discontinuations, and the inability to perform the initial 2-week assessment period from the H-IMT protocol study which may act as a familiarization period. The aetiology of bronchiectasis is quite diverse reflecting common practice in bronchiectasis, and we checked group equivalence with the severity of illness using BSI. The patients in this study were relatively younger, thus further study is needed to investigate how this technique would be tolerated by an older group. The lung function seems to be very close to the normal values. The effects of H-IMT in patients with a worse lung function require further investigation. In conclusion, this is the first study to show that an interval-based H-IMT protocol is a reliable method for achieving adequate loading in bronchiectasis patients. The H-IMT increased exercise capacity besides respiratory muscle strength and endurance, and may be included in pulmonary rehabilitation programmes for bronchiectasis patients. Further study is needed-specifically, welldesigned, sufficiently powered, randomized controlled trials to compare H-IMT with the other components of pulmonary rehabilitation, such as peripheral muscle training and aerobic training in patients with bronchiectasis, to understand exercise tolerance, dyspnoea perception, fatigue perception and the effect on QOL.
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